Search

Dexchlorpheniramine

Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. … The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions.

Carbazochrome

It is not FDA-approved but is available as tablets or IM/SC injections in the treatment of hemorrhages in a number of countries. … Carbazochrome is a hemostatic agent that promotes clotting, preventing blood loss from open wounds. It is an oxidation product of adrenaline which enhances the microcirculatory tone [A19747].

Terguride

Piclidenoson

CF101 is supplied as an oral drug and has an excellent safety profile. … It is also being considered for the treatment of other autoimmune-inflammatory disorders, such as Crohn's disease, psorasis and dry eye syndrome.

Recombinant alpha 1-antitrypsin

kallikrein, as well as neutrophil elastase. … The proteinase/antiproteinase balance is believed to be important for maintaining healthy skin. The rAAT topical gel (Dermolastin™) is indicated for patients with atopic dermatitis and psoriasis.

ALGRX 1207

ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. … ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.

Adenosine phosphate

Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. … Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]

ATL1101

ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis. … ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis.

Talizumab

TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.

Susoctocog alfa

AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the activated partial thromboplastin time (aPTT) assay, a conventional in vitro test for biological activity of … Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection.